Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.57 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.55 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.55 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096642 | 0.83 | PTGS1 (0.60) | P4HTMNPC1RAB9ASMN1; SMN2KCNQ3 | |
| SCHEMBL3096639 | 0.82 | KCNQ3 (0.52) | P4HTMNPC1RAB9ASMN1; SMN2KCNQ3 | |
| SCHEMBL4257363 | 0.82 | NPC1 (0.65) | NPC1RAB9AKCNQ3KCNQ2MEN1 | |
| SCHEMBL5934256 | 0.81 | P4HTM (0.60) | P4HTMNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL9566797 | 0.81 | P4HTM (0.67) | P4HTMNPC1RAB9ASMN1; SMN2KCNQ3 | |
| SCHEMBL4253868 | 0.81 | P4HTM (0.67) | P4HTMNPC1RAB9ASMN1; SMN2KCNQ3 | |
| SCHEMBL2055269 | 0.80 | RAB9A (0.67) | NPC1RAB9ASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL3643298 | 0.80 | P4HTM (0.65) | P4HTMNPC1RAB9ASMN1; SMN2KCNQ3 | |
| SCHEMBL3639325 | 0.79 | P4HTM (0.64) | P4HTMNPC1RAB9ASMN1; SMN2KCNQ3 | |
| SCHEMBL4255341 | 0.79 | NPC1 (0.81) | P4HTMNPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101765425-A | Use of benzamide derivatives for the treatment of CNS disorders | HOFFMANN LA ROCHE | 2010-06-30 | — | — | CN | disclosed |
| EP-2182935-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | P4HTM 2004/4885NPC1 869/4885RAB9A 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.